pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·Jun 11·1 min read
save

Federal probe finds private Medicare Advantage plans deny rehab care, then reverse on appeal

Jun 11, 2026·read at STAT ↗RegulatoryNegative

A federal investigation has revealed that the nation's largest Medicare Advantage insurers routinely deny post-acute rehabilitative services to older and disabled beneficiaries.

The review found that UnitedHealth Group's NaviHealth and Humana denied such care at rates higher than other plans, but many of those denials were later overturned after patients filed appeals.

Investigators say the pattern suggests insurers are using denials to increase profits, forcing seniors to battle for doctor-recommended treatment.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “STAT+: Private Medicare plans erect barriers to rehab care in pursuit of profit, federal investigators find”

read at STAT ↗
600 words · retrieved Jun 11
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
GILEAD

related stories

  • Jun 9Merck, Gilead report mixed outcomes in key lung cancer, HIV studiesBioPharma Dive
  • Jun 9Gilead and Merck’s latest trial success and flopSTAT
  • Jun 9Trodelvy misses in lung cancer, but Gilead and Merck have an HIV successEndpoints
  • Jun 9STAT+: Pharmalittle: We’re reading about a $10.6 billion GSK deal, an AstraZeneca obesity pill, and moreSTAT
  • May 29At ASCO, Merck makes case for a ‘cornerstone’ cancer drugBioPharma Dive